A5065798696- Systemic Lupus Erythematosus Research
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- Atherosclerosis and Cardiovascular Diseases
- Systemic Sclerosis and Related Diseases
- Salivary Gland Disorders and Functions
- Chronic Lymphocytic Leukemia Research
- Inflammatory Myopathies and Dermatomyositis
- Rheumatoid Arthritis Research and Therapies
- Immunodeficiency and Autoimmune Disorders
- Diabetes and associated disorders
- Renal Diseases and Glomerulopathies
- Lymphoma Diagnosis and Treatment
- Liver Diseases and Immunity
- Immune Cell Function and Interaction
- Platelet Disorders and Treatments
- Cytokine Signaling Pathways and Interactions
- Galectins and Cancer Biology
- Peripheral Neuropathies and Disorders
- Autoimmune and Inflammatory Disorders Research
- Glycosylation and Glycoproteins Research
- Cell Adhesion Molecules Research
- Heat shock proteins research
- Eosinophilic Disorders and Syndromes
- Celiac Disease Research and Management
University College London
2016-2025
MRC Centre for Regenerative Medicine
2025
Center for Rheumatology
2013-2024
University College London Hospitals NHS Foundation Trust
2015-2024
University College Hospital
2015-2024
United Nations Industrial Development Organization
2024
National Institute for Health Research
2022-2024
National Health Service
2023-2024
Memorial Sloan Kettering Cancer Center
2024
Tulane University
2024
The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the American College of Rheumatology (ACR) systemic lupus erythematosus (SLE) classification criteria in order to improve clinical relevance, meet stringent methodology requirements, incorporate new knowledge regarding immunology SLE.The were derived from a set 702 expert-rated patient scenarios. Recursive partitioning was used derive an initial rule that simplified refined based on SLICC physician...
Systemic lupus erythematosus has many guises, but the unifying feature is presence of antibodies against double-stranded DNA in almost all patients. This review provides data that show such autoantibodies cause renal lesions systemic erythematosus, and it emphasizes importance histones, histone fragments, other nuclear autoantigens.
Abstract Objective. Different sets of diagnostic criteria have been proposed for Sjögren's syndrome (SS), but none validated with a large series patients or in multicenter study. We conducted the present study involving 26 centers from 12 countries (11 Europe, plus Israel), goals reaching consensus on procedures SS and defining classification to be used epidemiologic surveys adopted by scientific community. Methods. The protocol was subdivided into two parts. For part I, questionnaires...
Abstract Objective B cells are likely to contribute the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion cells. The Exploratory Phase II/III SLE Evaluation Rituximab (EXPLORER) trial tested efficacy safety versus placebo in patients with moderately‐to‐severely active extrarenal SLE. Methods Patients entered ≥1 British Isles Lupus Assessment Group (BILAG) A score or ≥2 BILAG scores despite background immunosuppressant therapy, which was continued during...
Regulatory T cells have been clearly implicated in the control of disease murine models autoimmunity. The paucity data regarding role these lymphocytes human autoimmune has prompted us to examine their function patients with rheumatoid arthritis (RA). (CD4+CD25+) isolated from active RA displayed an anergic phenotype upon stimulation anti-CD3 and anti-CD28 antibodies, suppressed proliferation effector vitro. However, they were unable suppress proinflammatory cytokine secretion activated...
Abstract Objective To examine mortality rates in the largest systemic lupus erythematosus (SLE) cohort ever assembled. Methods Our sample was a multisite international SLE (23 centers, 9,547 patients). Deaths were ascertained by vital statistics registry linkage. Standardized ratio (SMR; of deaths observed to expected) estimates calculated for all and cause. The effects sex, age, duration, race, calendar‐year periods determined. Results overall SMR 2.4 (95% confidence interval 2.3–2.5)....
Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies not been compared in an international randomized, controlled trial. Here, we report comparison MMF and IVC as induction active nephritis a multinational, two-phase (induction maintenance) study. We randomly assigned 370 patients with classes III through V to open-label (target dosage 3 g/d) or (0.5 1.0 g/m(2)...
Objectives To develop recommendations for the management of adult and paediatric lupus nephritis (LN). Methods The available evidence was systematically reviewed using PubMed database. A modified Delphi method used to compile questions, elicit expert opinions reach consensus. Results Immunosuppressive treatment should be guided by renal biopsy, aiming complete response (proteinuria <0.5 g/24 h with normal or near-normal function). Hydroxychloroquine is recommended all patients LN. Because...
<h3>Objective:</h3> Systemic lupus erythematosus (SLE) is a complex disease with variable presentations, course and prognosis. We sought to develop evidence-based recommendations addressing the major issues in management of SLE. <h3>Methods:</h3> The EULAR Task Force on SLE comprised 19 specialists clinical epidemiologist. Key questions for were compiled using Delphi technique. A systematic search PubMed Cochrane Library Reports was performed McMaster/Hedges queries' strategies related...
To test the reliability of Systemic Lupus International Collaborating Clinics/American College Rheumatology (SLICC/ACR) Damage Index and Erythematosus Disease Activity (SLEDAI) in assessment patients with SLE.Ten SLE, representing a spectrum damage activity, were included. Each patient was examined by 6 10 physicians from 5 countries, lupus clinics. The SLICC/ACR used to assess accumulated damage, SLEDAI disease activity. order randomized according Youden square design.The detected...
Objectives To develop recommendations for the diagnosis, prevention and treatment of neuropsychiatric systemic lupus erythematosus (NPSLE) manifestations. Methods The authors compiled questions on prevalence risk factors, diagnosis monitoring, therapy prognosis NPSLE. A systematic literature search was performed evidence categorised based sample size study design. Results Systemic (SLE) patients are at increased several Common (cumulative incidence >5%) manifestations include...
Patients with rheumatoid arthritis have fewer regulatory B cells decreased function, which may be associated inflammation.
Maintenance therapy, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and prevent relapse after the initial control of lupus nephritis.
To gain preliminary evidence for the safety and efficacy of B lymphocyte depletion therapy in refractory systemic lupus erythematosus (SLE).Six female patients with active SLE, resistant to standard immunosuppressive therapy, were treated on an open-label basis. During a 2-week period, each patient received two 500-mg infusions rituximab, 750-mg cyclophosphamide, high-dose oral corticosteroids.No significant adverse events observed during followup. Patient 1 had not improved at 3 months but...
Objective. To devise a more discriminating version of the British Isles Lupus Assessment Group (BILAG) disease activity index and to show that it is reliable.
The British Isles Lupus Assessment Group (BILAG) index is a computerized for measuring clinical disease activity in systemic lupus erythematosus (SLE), which was developed according to the principle of physician's 'intention treat'. allocates separate alphabetic scores each eight organ-based systems; total score not calculated. This study demonstrated good between-rater reliability BILAG system. There no evidence bias between observers. had overall sensitivity (87%) and specificity (99%)...
Abstract Objective To investigate the safety and efficacy of MRA, a recombinant human anti–interleukin‐6 (anti–IL‐6) receptor monoclonal antibody IgG1 subclass that inhibits function IL‐6, in patients with established rheumatoid arthritis (RA). Methods A randomized, double‐blind, placebo‐controlled, dose‐escalation trial was conducted 45 active RA, as defined by American College Rheumatology (ACR) revised criteria. Patients were sequentially allocated to receive single intravenous dose...
Objective. To determine nephritis outcomes in a prospective multi-ethnic/racial SLE inception cohort. Methods. Patients the Systemic Lupus International Collaborating Clinics cohort (≤15 months of diagnosis) were assessed annually for estimated glomerular filtration rate (eGFR), proteinuria and end-stage renal disease (ESRD). Health-related quality life was measured by Short Form (36 questions) health survey questionnaire (SF-36) subscales, mental physical component summary scores. Results....